ADVANCED CANCER TREATMENT
OPTIONS IN CHINA

China combines several factors that are difficult to find together elsewhere: a large clinical trial pipeline, multiple approved cell therapies and biosimilars, advanced radiation technologies, mature interventional oncology programmes, and substantially lower costs for many advanced therapies. Chinese regulators have approved several CAR-T products, multiple PD-1 inhibitors, and emerging cell therapy platforms, while major academic and private hospitals run hundreds of active oncology trials. For patients facing limited options at home, this depth often opens realistic pathways. The challenge is choosing the right hospital and treatment for the specific case.

CAR-T cell therapy China has one of the world's largest CAR-T research ecosystems. Multiple CAR-T products are approved for relapsed or refractory B-cell lymphoma, multiple myeloma, and acute lymphoblastic leukaemia. Trial-based CAR-T programmes also target T-cell malignancies, AML, and selected solid tumours. Eligibility depends on diagnosis, antigen expression (CD19, BCMA, CD7, CD22, GPRC5D), disease burden, organ function, and prior therapy. Both autologous and allogeneic platforms are available depending on the centre. CAR-NK and other cell therapies CAR-NK therapy programmes — using natural killer cells engineered against CD19, CD33, BCMA, or solid tumour targets — are running across several Chinese centres, with potentially lower toxicity than CAR-T in selected settings. Gamma-delta T-cell therapies, NK cell infusions, and bispecific cell platforms are also accessible through trials. TIL therapy and tumour vaccines TIL (tumour-infiltrating lymphocyte) therapy is being actively developed in China for melanoma, cervical, lung, and head and neck cancers. Personalised neoantigen vaccines and dendritic cell vaccines are available through trial protocols at major centres. These are intensive treatments that require careful patient selection. Oncolytic virus therapy China was the first country to approve an oncolytic virus product (Oncorine, H101) for nasopharyngeal cancer in combination with chemotherapy. Newer oncolytic platforms — including modified herpes simplex, vaccinia, and adenovirus constructs — are available through trials for liver, head and neck, melanoma, and other tumours. Gendicine gene therapy Gendicine, an adenovirus-based p53 gene therapy, has been approved in China for selected head and neck and other cancers and is sometimes combined with radiation or chemotherapy. Eligibility is specific, and the therapy is best understood as one tool among several rather than a primary option for most patients. Proton and heavy-ion therapy China operates several proton therapy and carbon-ion therapy centres, including dedicated heavy-ion facilities. These are particularly relevant for paediatric cancers, brain and skull-base tumours, head and neck cancers, hepatocellular carcinoma, and cases where reducing long-term toxicity matters. Carbon-ion therapy availability is more limited globally, which is one reason patients travel specifically for it. BNCT, HIFU, TACE, and TARE Boron neutron capture therapy (BNCT) is available at selected Chinese facilities for recurrent head and neck cancers and some brain tumours. HIFU (high-intensity focused ultrasound) is widely available for liver, pancreatic, kidney, bone, and selected gynaecological tumours. TACE and TARE are well established for hepatocellular carcinoma and liver-dominant metastatic disease, often combined with systemic therapy or immunotherapy. Affordable immunotherapy and targeted therapy Several China-approved PD-1 inhibitors — including tislelizumab, sintilimab, toripalimab, and camrelizumab — are substantially more affordable than originator drugs. Biosimilars for trastuzumab, bevacizumab, rituximab, and several TKIs are also widely used. For patients facing long-term immunotherapy or targeted therapy, this can meaningfully change what is sustainable. Clinical trials China runs one of the largest active oncology trial pipelines globally, covering CAR-T and CAR-NK in solid tumours, KRAS and HER2 inhibitors, antibody-drug conjugates, bispecific antibodies, novel checkpoint targets including LAG-3 and TIGIT, and combination regimens. International patient access varies by trial and centre, and eligibility is strict.

Case review — diagnosis, biomarkers, and prior treatment are reviewed to assess whether China-based options are realistic and which categories are most relevant. Hospital and trial matching — reports are shared with appropriate Chinese oncology teams, cell therapy units, or trial centres for structured feedback before any travel. Treatment planning — approved therapies, biosimilars, and clinical trial pathways are mapped against the patient's case and goals. Cost and logistics — patients receive guidance on realistic cost ranges, expected stay duration, visa, accommodation, interpreter support, and follow-up planning. Coordination and continuity — admission, communication with hospital teams, and continuity of care after returning home are coordinated through a single point of contact.

China's oncology landscape spans national cancer centres, university teaching hospitals, dedicated cell therapy units, private oncology hospitals, and specialised proton and heavy-ion centres. The same treatment category may have very different eligibility rules, cost structures, admission timelines, and outcomes depending on the centre. CancerFax helps patients identify the most relevant pathway based on case volume, treatment expertise, trial portfolio, and international patient experience — rather than choosing a hospital by name alone.

Frequently Asked Questions

Answers to common questions from patients and families.